{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T12:36:41Z","timestamp":1794573401956,"version":"4.9.1"},"reference-count":50,"publisher":"American Society of Hematology","issue":"2","license":[{"start":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T00:00:00Z","timestamp":1701734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,23]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Chimeric antigen receptor (CAR) T-cell therapies have shown significant benefits in the treatment of hematologic malignancies, such as B-cell acute lymphoblastic leukemia (B-ALL) and B-cell lymphoma. Despite the therapeutic advances offered by these innovative treatments, failures are still observed in 15% to 40% of patients with B-ALL and &amp;gt;50% of patients with B-cell lymphoma. Several hypotheses have emerged including CD19-negative or -positive relapses, low CAR T-cell activation and\/or expansion in\u00a0vivo, or T-cell exhaustion. To date, in the European Union, CAR T cells granted with marketing authorization are autologous and thus associated with a strong heterogeneity between products. Indeed, the manufacturing of a single batch requires cellular starting material collection by apheresis for each patient, with variable cellular composition, and then challenging pharmaceutical companies to standardize as much as possible the production process. In addition, these cost and time-consuming therapies are associated with a risk of manufacturing failure reaching 25%. Thus, there is a growing need to identify early risk factors of unsuccessful production and\/or therapeutic escape. Quality of the apheresis product, pathology progression, as well as previous treatments have been reported as predictive factors of the variability in clinical response. The aim of this review is to report and discuss predictive factors that could help to anticipate the manufacturing success and clinical response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011992","type":"journal-article","created":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T17:05:44Z","timestamp":1701795944000},"page":"337-342","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":101,"title":["Early predictive factors of failure in autologous CAR T-cell manufacturing and\/or efficacy in hematologic malignancies"],"prefix":"10.1182","volume":"8","author":[{"given":"Cl\u00e9mentine","family":"Baguet","sequence":"first","affiliation":[{"name":"1Universit\u00e9 Paris Cit\u00e9, Assistance Publique \u2013 H\u00f4pitaux de Paris, H\u00f4pital Saint-Louis, Unit\u00e9 de Th\u00e9rapie Cellulaire, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Larghero","sequence":"additional","affiliation":[{"name":"1Universit\u00e9 Paris Cit\u00e9, Assistance Publique \u2013 H\u00f4pitaux de Paris, H\u00f4pital Saint-Louis, Unit\u00e9 de Th\u00e9rapie Cellulaire, Paris, France"},{"name":"2Universit\u00e9 Paris Cit\u00e9, Assistance Publique \u2013 H\u00f4pitaux de Paris, H\u00f4pital Saint-Louis, Centre MEARY de Th\u00e9rapie Cellulaire et G\u00e9nique, Paris, France"},{"name":"3INSERM, Centre d\u2019investigation Clinique de Bioth\u00e9rapies CBT501, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3413-0463","authenticated-orcid":false,"given":"Miryam","family":"Mebarki","sequence":"additional","affiliation":[{"name":"1Universit\u00e9 Paris Cit\u00e9, Assistance Publique \u2013 H\u00f4pitaux de Paris, H\u00f4pital Saint-Louis, Unit\u00e9 de Th\u00e9rapie Cellulaire, Paris, France"},{"name":"3INSERM, Centre d\u2019investigation Clinique de Bioth\u00e9rapies CBT501, Paris, France"},{"name":"4Facult\u00e9 de pharmacie, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,1,11]]},"reference":[{"key":"2024012221513892700_bib1","unstructured":"European Medicines Agency\n          . CAT Quarterly Highlights and Approved ATMPs. Accessed 19 November 2023. https:\/\/www.ema.europa.eu\/en\/documents\/report\/cat-quarterly-highlights-approved-atmps-january-2023_en.pdf."},{"key":"2024012221513892700_bib2","unstructured":"European Medicines Agency\n          . Kymriah. Accessed 20 November 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kymriah."},{"key":"2024012221513892700_bib3","unstructured":"European Medicines Agency\n          . Yescarta. Accessed 10 March 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/yescarta."},{"issue":"4","key":"2024012221513892700_bib4","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1182\/blood-2018-02-778530","article-title":"Acute lymphoblastic leukemia in adolescent and young adults: treat as adults or as children?","volume":"132","author":"Boissel","year":"2018","journal-title":"Blood"},{"issue":"22","key":"2024012221513892700_bib5","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Advances"},{"issue":"26","key":"2024012221513892700_bib6","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024012221513892700_bib7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"2024012221513892700_bib8","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.omtm.2021.06.014","article-title":"Depletion of high-content CD14+ cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturing","volume":"22","author":"Wang","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"10 suppl","key":"2024012221513892700_bib9","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.1016\/j.bulcan.2021.05.004","article-title":"Les m\u00e9dicaments de th\u00e9rapie g\u00e9nique CAR-T cells : statuts r\u00e9glementaires et circuits pharmaceutiques en Europe et en France","volume":"108","author":"de Jorna","year":"2021","journal-title":"Bull Cancer"},{"issue":"2","key":"2024012221513892700_bib10","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in\u00a0vivo","volume":"30","author":"Sommermeyer","year":"2016","journal-title":"Leukemia"},{"issue":"15","key":"2024012221513892700_bib11","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.1182\/bloodadvances.2022007057","article-title":"Real-world characteristics of T-cell apheresis and clinical response to tisagenlecleucel in B-cell lymphoma","volume":"6","author":"Cuffel","year":"2022","journal-title":"Blood Advances"},{"issue":"21","key":"2024012221513892700_bib12","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Advances"},{"issue":"303","key":"2024012221513892700_bib13","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"issue":"12","key":"2024012221513892700_bib14","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1038\/s41375-021-01281-7","article-title":"Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia | Leukemia","volume":"35","author":"Dourthe","year":"2021","journal-title":"Leukemia"},{"issue":"5","key":"2024012221513892700_bib15","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1182\/bloodadvances.2021006563","article-title":"HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma","volume":"7","author":"Bourbon","year":"2022","journal-title":"Blood Adv"},{"issue":"10","key":"2024012221513892700_bib16","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","article-title":"A\u00a0real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma","volume":"28","author":"Bachy","year":"2022","journal-title":"Nat Med"},{"issue":"320","key":"2024012221513892700_bib17","doi-asserted-by":"crossref","first-page":"320ra3","DOI":"10.1126\/scitranslmed.aad5222","article-title":"Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies","volume":"8","author":"Singh","year":"2016","journal-title":"Sci Transl Med"},{"issue":"4","key":"2024012221513892700_bib18","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1158\/2159-8290.CD-18-1314","article-title":"Na\u00efve T-cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers","volume":"9","author":"Das","year":"2019","journal-title":"Cancer Discov"},{"issue":"2","key":"2024012221513892700_bib19","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/bjh.18831","article-title":"Risk factors for CAR-T cell manufacturing failure among DLBCL patients: a nationwide survey in Japan","volume":"202","author":"Jo","year":"2023","journal-title":"Br J Haematol"},{"issue":"22","key":"2024012221513892700_bib20","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1182\/bloodadvances.2019000692","article-title":"CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy","volume":"3","author":"Pillai","year":"2019","journal-title":"Blood Advances"},{"key":"2024012221513892700_bib21","unstructured":"Taraseviciute\n              A\n            , SteinbergSM, MyersRM, . Pre-CAR blinatumomab is associated with increased post-CD19 CAR relapse and decreased event free survival. American Society of Hematology. 2022. Meeting abstract, 2020. Accessed 21 May. https:\/\/ash.confex.com\/ash\/2020\/webprogram\/Paper139260.html."},{"issue":"1","key":"2024012221513892700_bib22","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1038\/s41467-022-29175-x","article-title":"Single-cell RNA sequencing coupled to TCR profiling of large granular lymphocyte leukemia T cells","volume":"13","author":"Gao","year":"2022","journal-title":"Nat Commun"},{"issue":"3","key":"2024012221513892700_bib23","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/jha2.479","article-title":"CAR-T cells derived from multiple myeloma patients at diagnosis have improved cytotoxic functions compared to those produced at relapse or following daratumumab treatment","volume":"3","author":"Abecassis","year":"2022","journal-title":"EJHaem"},{"issue":"1","key":"2024012221513892700_bib24","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/leu.2016.262","article-title":"Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms","volume":"31","author":"Ruella","year":"2017","journal-title":"Leukemia"},{"issue":"9","key":"2024012221513892700_bib25","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"issue":"8","key":"2024012221513892700_bib26","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J\u00a0Clin Invest"},{"issue":"18","key":"2024012221513892700_bib27","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1182\/blood-2011-12-400044","article-title":"Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning","volume":"119","author":"Pegram","year":"2012","journal-title":"Blood"},{"issue":"11","key":"2024012221513892700_bib28","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1038\/s41375-021-01196-3","article-title":"Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia","volume":"35","author":"Perica","year":"2021","journal-title":"Leukemia"},{"issue":"6","key":"2024012221513892700_bib29","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR\u2013T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J\u00a0Clin Invest"},{"issue":"17","key":"2024012221513892700_bib30","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","article-title":"The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells","volume":"133","author":"Hirayama","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2024012221513892700_bib31","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1615\/CritRevImmunol.2018019497","article-title":"Effect of lymphodepletion on donor T cells and the role of recipient cells persisting after cytotoxic treatments in cancer immunotherapies","volume":"37","author":"Watanabe","year":"2017","journal-title":"Crit Rev Immunol"},{"issue":"5","key":"2024012221513892700_bib32","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/trf.14003","article-title":"Autologous lymphapheresis for the production of chimeric antigen receptor T cells","volume":"57","author":"Allen","year":"2017","journal-title":"Transfusion"},{"issue":"3","key":"2024012221513892700_bib33","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jcyt.2022.10.012","article-title":"A\u00a0novel predictive algorithm to personalize autologous T-cell harvest for chimeric antigen receptor T-cell manufacture","volume":"25","author":"O\u2019Reilly","year":"2023","journal-title":"Cytotherapy"},{"issue":"9","key":"2024012221513892700_bib34","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/gt.2010.59","article-title":"Ex\u00a0vivo culture of chimeric antigen receptor T cells generates functional CD8+ T cells with effector and central memory-like phenotype","volume":"17","author":"Neeson","year":"2010","journal-title":"Gene Ther"},{"issue":"7","key":"2024012221513892700_bib35","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jcyt.2016.04.003","article-title":"Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells","volume":"18","author":"Stroncek","year":"2016","journal-title":"Cytotherapy"},{"issue":"4","key":"2024012221513892700_bib36","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1182\/bloodadvances.2022007246","article-title":"Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium","volume":"7","author":"Stefanski","year":"2023","journal-title":"Blood Advances"},{"issue":"17","key":"2024012221513892700_bib37","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a Phase I Anti-CD22 CAR T-Cell Trial","volume":"38","author":"Shah","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"10402","key":"2024012221513892700_bib38","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"issue":"5","key":"2024012221513892700_bib39","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/trf.15287","article-title":"Effects of starting cellular material composition on chimeric antigen receptor T-cell expansion and characteristics","volume":"59","author":"Elavia","year":"2019","journal-title":"Transfusion"},{"issue":"11","key":"2024012221513892700_bib40","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1182\/bloodadvances.2020003959","article-title":"Axicabtagene ciloleucel in vivo expansion and treatment outcome in aggressive B-cell lymphoma in a real-world setting","volume":"5","author":"Ayuk","year":"2021","journal-title":"Blood advances"},{"issue":"10","key":"2024012221513892700_bib41","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/nm.2446","article-title":"A human memory T-cell subset with stem cell-like properti","volume":"17","author":"Gattioni","year":"2011","journal-title":"Nat Med"},{"issue":"9","key":"2024012221513892700_bib42","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/eji.202049064","article-title":"CAR T cells: building on the CD19 paradigm","volume":"51","author":"Levin","year":"2021","journal-title":"Eur J Immunol"},{"issue":"19","key":"2024012221513892700_bib43","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Advances"},{"issue":"95","key":"2024012221513892700_bib44","doi-asserted-by":"crossref","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T\u00a0cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"issue":"5","key":"2024012221513892700_bib45","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"issue":"24","key":"2024012221513892700_bib46","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","article-title":"Closely related T-memory stem cells correlate with in\u00a0vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15","volume":"123","author":"Xu","year":"2014","journal-title":"Blood"},{"issue":"10266","key":"2024012221513892700_bib47","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","article-title":"Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies","volume":"396","author":"Benjamin","year":"2020","journal-title":"Lancet"},{"issue":"suppl 1","key":"2024012221513892700_bib48","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1182\/blood-2022-169928","article-title":"AMELI-01: a phase I trial of UCART123v1.2, an anti- CD123 allogeneic CAR-T cell product, in adult patients with relapsed or refractory (R\/R) CD123+ acute myeloid leukemia","volume":"140","author":"Sallman","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2024012221513892700_bib49","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1182\/blood-2022-168877","article-title":"Phase 1 dose escalation study of the rapidly switchable universal CAR-T therapy Unicar-T-CD123 in relapsed\/refractory AML","volume":"140","author":"Ehninger","year":"2022","journal-title":"Blood"},{"issue":"10","key":"2024012221513892700_bib50","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nbt.2678","article-title":"Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy","volume":"31","author":"Themeli","year":"2013","journal-title":"Nat Biotechnol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/2\/337\/2210565\/blooda_adv-2023-011992-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/2\/337\/2210565\/blooda_adv-2023-011992-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T16:52:01Z","timestamp":1705942321000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/2\/337\/506509\/Early-predictive-factors-of-failure-in-autologous"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,11]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,1,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011992","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,11]]}}}